Background: This retrospective study evaluated the incidence of brain metastases in a subgroup of patients with metastatic renal cell carcinoma (RCC) who were randomly assigned to receive sorafenib, an oral multikinase inhibitor (400 mg b.i.d.), versus placebo in the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET).
introduction
Renal cell carcinoma (RCC) arises from the renal epithelium and accounts for 75% of all renal cancers [1] . The prognosis for patients with RCC is very poor, with <10% of patients surviving at 5 years [2] . Moreover, 25% of patients present with advanced disease, including locally invasive or metastatic renal cell carcinoma (mRCC), and one-third of the patients who undergo resection of localised disease will have disease recurrence [3] . Most patients respond poorly to cytokine therapy, and, until recently, the median survival for patients with metastatic disease was reported to be 13 months [4, 5] .
RCC is a notoriously chemoresistant hypervascularised tumour type, often associated with up-regulated vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFr) activity [1, 6] . Several different strategies targeting various components of the VEGF pathway have yielded clinically relevant therapies for mRCC [1] . Sorafenib is an orally active multikinase inhibitor that blocks intracellular kinases in the Raf/MEK/ERK pathway that are involved in tumour proliferation, such as Raf-1, as well as those promoting angiogenesis, including VEGFr-2, VEGFr-3, Flt-3, platelet-derived growth factor receptor b, and c-KIT [7, 8] . In a phase II placebo-controlled trial of sorafenib in patients with mRCC, the median progression-free survival (PFS) from the time of randomisation was significantly longer in patients treated with sorafenib than in those treated with placebo (24 versus 6 weeks; P = 0.0087) [9] . The phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) was one of the largest randomised controlled trials in RCC carried out to date, involving 903 patients with advanced RCC; 451 were treated with sorafenib and 452 received placebo. In this trial, sorafenib treatment was associated with a twofold increase in median PFS compared with placebo (5.5 versus 2.8 months; P < 0.001) [10] . TARGET established oral sorafenib as a safe and effective treatment of mRCC and formed the basis for its marketing approval by the USA Food and Drug Administration in December 2005 and the European Medicines Agency in July 2006 for the treatment of advanced RCC.
Brain metastasis is a major cause of morbidity and mortality in human malignancy [11] . The incidence of brain metastasis is estimated to be 170 000/year in the United States, which is 10 times higher than that of primary malignant brain tumours. Previous reports have indicated that 20%-40% of patients with systemic cancer will develop metastases involving the central nervous system (CNS) during the course of their disease [12] . In adults, metastases to the brain most commonly arise from primary tumours of the lung (50%-60%), breast (15%-20%), skin (melanoma: 5%-10%), and the gastrointestinal tract (4%-6%) [13, 14] . In patients with RCC, the incidence of brain metastasis is 10%-20% [15, 16] , making these patients a significant proportion of the advanced RCC population.
Because patients with metastatic cancer in the CNS are often excluded from experimental treatment, the efficacy of new systemic cancer therapies is difficult to establish in this population [17] . Furthermore, a recent report reviewing five cases of intracerebral haemorrhage in mRCC patients with brain metastases following treatment with either sorafenib or sunitinib raised the concern that antiangiogenic therapies may increase the risk for CNS haemorrhage in patients with brain metastases [18] . To further explore the possible associations of treatment with sorafenib and its impact on brain metastases, we conducted this retrospective analysis looking at the incidence of brain metastases in patients treated with sorafenib compared with that in the placebo group in a subgroup of patients from TARGET.
patients and methods patients
This study is a retrospective analysis of the incidence of brain metastases in a subgroup of patients from TARGET. The study design and patient inclusion criteria for TARGET have been previously described [10] . Briefly, this was a phase III, multicentre, randomised, double-blind, placebo-controlled trial in patients with unresectable RCC and/or mRCC who had undergone one prior systemic therapy. Other inclusion criteria included low-or intermediate-risk Memorial Sloan-Kettering Cancer Center (MSKCC) score [5] and adequate organ function. Patients were stratified by MSKCC score and country of enrolment and then randomly assigned to receive either continuous treatment with oral sorafenib 400 mg b.i.d. (n = 451) or placebo (n = 452). Patients were to remain on the study drug until disease progression or discontinuation due to adverse events or death, but those in the sorafenib group could continue treatment with open-label drug beyond the end point of radiologic progression at the discretion of the investigator.
A total of 903 patients were enrolled in TARGET. A single planned formal analysis of PFS in January 2005 demonstrated an advantage for the sorafenib group (hazard ratio = 0.51; P < 0.001), leading to a Data Monitoring Committee recommendation to close the study and cross patients on placebo over to active therapy.
For the purpose of this report, data from 139 patients who were enrolled in TARGET at the Gustave Roussy Institute (Villejuif, France) (n = 85) and the Central Clinical Hospital of Military Academy (Warsaw, Poland) (n = 54; one patient lost to follow-up) from January 2000 to December 2003 were retrospectively analysed for the incidence of brain metastases due to RCC. The only selection criterion for the present subanalysis was participation in TARGET at these institutions.
variables
The following data were collected from the patients' medical history: age, site and number of metastases, MSKCC risk category, Eastern Cooperative Oncology Group performance status, first-line therapy, and treatment arm (sorafenib or placebo). Per study protocol, all patients had a negative baseline brain computed tomography (CT) scan. During the course of the study, patients were followed clinically without prescheduled CT or other CNS scans. The occurrence of brain metastases during follow-up was documented via medical chart review; brain metastases were usually detected following the onset of neurologic symptoms.
statistical analyses
The association between treatment (sorafenib versus placebo) and the occurrence of brain metastases was evaluated by a Cox model of univariate analysis. The incidence of brain metastases was analysed using the Kaplan-Meier method. The starting dates for the Cox and Kaplan-Meier analyses were the dates of enrolment in TARGET. Treatment-related differences in the incidence of brain metastases were evaluated by the chisquare test in a univariate analysis. All reported P values were two sided, with P values <0.05 being considered statistically significant. Data were analysed using SAS software.
results patient characteristics
One hundred and thirty-nine patients with advanced RCC from the Institut Gustave Roussy, Villejuif, France (n = 85), and Central Clinical Hospital of Military Medical Academy, Warsaw, Poland (n = 54), were retrospectively analysed after their participation in the original TARGET; these patients made up the subpopulation examined in this paper. They represent 15.4% of the total study population of 903 patients. Within the TARGET participant pool, 451 and 452 patients were randomly assigned to receive sorafenib or placebo, respectively. The demographic and baseline characteristics of the intent-to-treat population have previously been described [10] . Table 1 summarises the patient characteristics of the present TARGET subgroup, which is composed of 139 patients who were examined for brain metastases. As shown, patient characteristics were comparable in the sorafenib (n = 70) and placebo (n = 69) groups. The median follow-up time for these 139 patients was 12.5 months. The median PFS for patients in the sorafenib arm was 4.1 versus 2.7 months in the placebo arm, and the median overall survival was 8.9 and 8.7 months for the sorafenib and placebo arms, respectively.
incidence of brain metastases
Ten patients (7%) presented with brain metastases after a median follow-up of 19.28 months ( Table 2) . As shown in Figure 1 , the overall incidence of brain metastases was 3% and 12% in patients treated with sorafenib therapy and placebo, respectively (P = 0.04, log-rank test). The 1-and 2-year incidences of brain metastases were 3% and 0%, respectively, for patients in the sorafenib group, compared with 7% and 13%, respectively, for patients who received placebo. Of note, 8 of the 10 brain metastases occurred >6 months following the start of treatment (Table 3 ). The overall incidence of brain metastases was significantly lower in patients treated with sorafenib than in patients who received placebo (3% versus 12%; P = 0.008). The incidence of brain metastases was also significantly lower in sorafenib-treated patients than in placebo-treated patients after 1 (P = 0.003) and 2 years (P < 0.05) of treatment (Figures 1 and 2) . Univariate analyses were carried out to identify any variables that correlated with brain metastases in this subgroup of patients (Table 4 ). The administration of sorafenib therapy was the only predictive factor to affect the occurrence of brain metastases in patients with advanced RCC. A total of 2 of 70 (2.9%) patients who received sorafenib therapy developed a brain metastasis compared with 8 of 69 (11.6%) patients who were given placebo (P = 0.04, Cox analysis).
discussion
In this retrospective study, we have shown that the administration of sorafenib therapy is associated with a lower incidence of brain metastases than placebo in patients with advanced RCC in whom prior first-line therapy had failed. Sorafenib treatment significantly reduced the overall, 1-, and 2-year incidences of brain metastases compared with the incidences in patients who received placebo. The small study size limits the strength of conclusions that can be drawn, but these observations highlight the need for further research on this important clinical concern.
The incidence of brain metastases in the placebo arm (12%) was similar to what has been reported in previous studies: 10%-20% [15] [16] [17] 19] . It should be noted that all patients in the TARGET study were free of brain metastases at baseline, as determined by normal brain CT scans at the start of treatment; Annals of Oncology original article therefore, the lower incidence of metastases to the brain as disease progressed can possibly be attributed to treatment with sorafenib [10] . However, this conclusion has to be made with caution because of the small number of patients with brain metastases included in this subanalysis. This antimetastatic effect may be achieved through two different potential molecular targets of sorafenib. On the one hand, sorafenib may act on the primary tumour to prevent the formation of metastases. Angiogenesis is necessary for continued tumour growth [14] . Without vascular growth, tumour mass is restricted to a size dictated by limits of diffusion within a tissue. The angiogenic switch is influenced by a complex interplay of proangiogenic molecules, such as VEGF, and antiangiogenic molecules, such as angiostatin. Further evidence for the role of VEGF in brain metastases has been reported by Kim et al. [20] , who concluded that VEGF expression contributes to the ability of breast cancer cells to form brain metastases in an animal model. Thus, sorafenib may limit metastatic spread by restricting tumour growth [10] . Alternatively, sorafenib may penetrate the brain and target the metastatic site directly, potentially acting on brain micrometastases. The brain is among the best-perfused organs of the body, and the distribution of metastases within the brain correlates with blood flow [21] . Unfortunately, malignancies that grow within the CNS are refractory to most chemotherapy regimens because few pharmacologically active compounds can cross the blood-brain barrier (BBB) [22, 23] . Drug entry across the BBB depends on its chemical properties, such as hydrophobicity and size. In addition, the BBB may become permeable around the tumour [23] . In healthy tissue, molecules >180 kDa are unlikely to passively leak from the vasculature, but another tyrosine kinase inhibitor (TKI), imatinib, can cross the BBB [24] . Although the distribution of sorafenib in the brain is unknown, both drugs have molecular masses of 600 Da, indicating that sorafenib might also be able to enter metastatic sites in the brain. In support of this hypothesis, there is a report of objective response of brain metastases under TKI treatment in mRCC [25] . Further, a retrospective analysis of 91 patients and several case studies report that brain metastases from RCC responded to sunitinib therapy [26] [27] [28] . Brain metastases, however, were the first signs of tumour progression in patients receiving sunitinib therapy in the retrospective analysis, indicating that brain metastasis was a frequent mode of progression in their patient sample [26] .
Recently, several studies demonstrated activity of antiangiogenic therapies in primary brain tumours [29] . Glioblastoma multiforme (GBM) represents the most common glioma histology and has a poor prognosis despite the use of multimodality treatment (with surgery, radiation, and chemotherapy), with a median survival of 12-15 months. Recurrent GBM is a lethal disease, with currently available treatment options having a limited impact on outcome. In Annals of Oncology recent years, our knowledge of the molecular pathogenesis of GBM has significantly expanded [30] . In particular, GBM is characterised by intense angiogenesis, which is a key event in tumour growth and progression. Treatments with antiangiogenics that can cross the BBB may be a useful means of attack against GBM. For example, a recent phase II study presented at the 2006 American Society of Clinical Oncology meeting has shown that a combination of bevacizumab and irinotecan is an effective treatment of recurrent GBM [31] . Several clinical trials are now under way that evaluate the safety and efficacy of sorafenib in combination with other therapies in the treatment of GBM (www.clinicaltrials.gov, accessed 23 February 2009).
With additional clinical trial data, both from retrospective and prospective studies, antiangiogenic therapy with the oral multikinase inhibitor sorafenib could prove to be an effective preventive treatment of brain metastases in advanced RCC. Further studies are warranted to investigate the antimetastatic effects of sorafenib in advanced RCC in first-line and subsequent-line therapies and to determine the mechanism by which sorafenib exerts these effects in the brain.
conclusions
Our data show that treatment of advanced RCC with sorafenib may be associated with a lower incidence of brain metastases within this subgroup of patients from TARGET. Sorafenib may reduce metastases by suppressing the progression of visceral disease or by inhibiting brain metastasis angiogenesis. This result should be confirmed in large randomised trials with antiangiogenic therapies. 
